LLY

784.56

-0.86%↓

JNJ

150.85

-0.97%↓

NVO

74.09

-0.39%↓

ABBV

185.38

+0.09%↑

UNH

307.09

-0.49%↓

LLY

784.56

-0.86%↓

JNJ

150.85

-0.97%↓

NVO

74.09

-0.39%↓

ABBV

185.38

+0.09%↑

UNH

307.09

-0.49%↓

LLY

784.56

-0.86%↓

JNJ

150.85

-0.97%↓

NVO

74.09

-0.39%↓

ABBV

185.38

+0.09%↑

UNH

307.09

-0.49%↓

LLY

784.56

-0.86%↓

JNJ

150.85

-0.97%↓

NVO

74.09

-0.39%↓

ABBV

185.38

+0.09%↑

UNH

307.09

-0.49%↓

LLY

784.56

-0.86%↓

JNJ

150.85

-0.97%↓

NVO

74.09

-0.39%↓

ABBV

185.38

+0.09%↑

UNH

307.09

-0.49%↓

Search

Alkermes PLC

Cerrado

SectorSalud

29.28 -1.61

Resumen

Variación precio

24h

Actual

Mínimo

29.13

Máximo

29.45

Métricas clave

By Trading Economics

Ingresos

-124M

22M

Ventas

-123M

307M

P/B

Media del Sector

14.205

50.857

BPA

0.291

Margen de beneficio

7.329

Empleados

1,800

EBITDA

-168M

14M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 meses

+37.85% upside

Dividendos

By Dow Jones

Próximas Ganancias

23 jul 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

-906M

4.9B

Apertura anterior

30.89

Cierre anterior

29.28

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

154 / 381 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Weak Bullish Evidence

Alkermes PLC Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

19 jun 2025, 15:04 UTC

Adquisiciones, fusiones, absorciones

UniCredit's Banco BPM Bid Gets Conditional EU Nod -- Update

19 jun 2025, 14:33 UTC

Adquisiciones, fusiones, absorciones

UniCredit's Banco BPM Bid Gets Conditional EU Nod

19 jun 2025, 23:42 UTC

Charlas de Mercado

Nikkei May Trade Rangebound Amid Uncertainty Over Israel-Iran Conflict -- Market Talk

19 jun 2025, 20:50 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

19 jun 2025, 20:50 UTC

Charlas de Mercado
Ganancias

Auto & Transport Roundup: Market Talk

19 jun 2025, 20:38 UTC

Adquisiciones, fusiones, absorciones

Home Depot Bid Kicks Off a Battle for $5 Billion Building-Products Company -- WSJ

19 jun 2025, 20:38 UTC

Adquisiciones, fusiones, absorciones

Home Depot Privately Made Bid for Building-Products Distributor GMS, Sources Say -- WSJ

19 jun 2025, 20:38 UTC

Adquisiciones, fusiones, absorciones

Competing Offers Could Prompt Bidding War for GMS, Sources Say -- WSJ

19 jun 2025, 20:38 UTC

Adquisiciones, fusiones, absorciones

Offer From Home Depot Comes as QXO Makes Unsolicited Proposal at $95.20 Per Share -- WSJ

19 jun 2025, 17:02 UTC

Adquisiciones, fusiones, absorciones

Worthington Buys Elgen Manufacturing for About $93M, Funded With Cash on Hand

19 jun 2025, 17:01 UTC

Adquisiciones, fusiones, absorciones

Worthington Enterprises Says Elgen Will Become Part of Its Building Products Segment

19 jun 2025, 17:01 UTC

Adquisiciones, fusiones, absorciones

Worthington Enterprises Acquires Elgen Manufacturing >WOR

19 jun 2025, 16:20 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

19 jun 2025, 16:20 UTC

Charlas de Mercado
Ganancias

Auto & Transport Roundup: Market Talk

19 jun 2025, 15:37 UTC

Charlas de Mercado

European Gas Soars on Middle East Escalation Fears -- Market Talk

19 jun 2025, 15:16 UTC

Charlas de Mercado

Copper Prices Look Set to Fall Over Third Quarter, Citi Says -- Market Talk

19 jun 2025, 15:16 UTC

Charlas de Mercado

Market Talk Roundup: Latest on U.S. Politics

19 jun 2025, 15:10 UTC

Charlas de Mercado

Dollar Rises as Israel-Iran Conflict Intensifies -- Market Talk

19 jun 2025, 15:10 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

19 jun 2025, 15:02 UTC

Charlas de Mercado

Oil Climbs 2% as Israel-Iran Tensions Mount, With U.S. Role in Focus -- Market Talk

19 jun 2025, 14:15 UTC

Adquisiciones, fusiones, absorciones

EU: UniCredit Committed to Divest 209 Physical Branches in Overlap Areas Across Italy

19 jun 2025, 14:15 UTC

Adquisiciones, fusiones, absorciones

EU: UniCredit Commitments Fully Address Competition Concerns Identified

19 jun 2025, 14:15 UTC

Adquisiciones, fusiones, absorciones

EU Rejected Request From Italian Competition Authority to Refer Deal for National Review

19 jun 2025, 14:15 UTC

Adquisiciones, fusiones, absorciones

EU Approves UniCredit's Acquisition of Banco BPM, Subject to Conditions

19 jun 2025, 14:15 UTC

Adquisiciones, fusiones, absorciones

EU Says There Are No Compelling Reasons to Justify Referral to Italy

19 jun 2025, 13:58 UTC

Charlas de Mercado

Market Talk Roundup: BOE Holds Rates as Focus Turns to Likely August Cut

19 jun 2025, 13:58 UTC

Charlas de Mercado

Market Talk Roundup: BOE Holds Rates as Focus -2-

19 jun 2025, 13:38 UTC

Charlas de Mercado

Canadian Small Firms Appear to Be Coping With Tariffs -- Market Talk

19 jun 2025, 13:33 UTC

Charlas de Mercado

BOE Likely to Cut Rates If Firms' Pricing Power Weakens -- Market Talk

19 jun 2025, 13:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

Comparación entre iguales

Cambio de precio

Alkermes PLC Esperado

Precio Objetivo

By TipRanks

37.85% repunte

Estimación a 12 meses

Media 40.43 USD  37.85%

Máximo 52 USD

Mínimo 30 USD

De acuerdo con 14 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Alkermes PLC Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

14 ratings

9

Comprar

5

Mantener

0

Vender

Puntuación técnica

By Trading Central

27.95 / 30.91Soporte y Resistencia

Corto Plazo

Weak Bullish Evidence

Medio plazo

Strong Bearish Evidence

Largo Plazo

Strong Bullish Evidence

Sentimiento

By Acuity

154 / 381 Clasificación en Salud

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Alkermes PLC

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS). The Company's products include ARISTADA, VIVITROL, INVEGA SUSTENNA, XEPLION, INVEGA TRINZA, TREVICTA, RISPERDAL CONSTA, AMPYRA, FAMPYRA, BYDUREON, Aripiprazole lauroxil, ALKS 5461, ALKS 3831, ALKS 8700, ALKS 6428, ALKS 4230 and ALKS 7119. The Company's product platforms include injectable extended-release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release (OCR) technology. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia.